Home / Health / 'It's nightmarish': Uphill task as Bharat Biotech gears for vaccine rollout

'It's nightmarish': Uphill task as Bharat Biotech gears for vaccine rollout

Bharat has already produced about 10 million doses of its Covaxin shot, ahead of an anticipated roll out by the middle of next year

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma

Premium

The lack of phase III trial data didn’t stop Bharat from applying for emergency use authorization this month.

4 min read Last Updated : Dec 23 2020 | 1:27 AM IST

The developer of India’s leading indigenous coronavirus vaccine is already producing millions of doses of its yet-to-be-approved candidate, but the thought of supplying enough shots for half the country’s nearly 1.4 billion people can seem daunting at times.

“It’s nightmarish,” said Suchitra Ella, joint managing director of Bharat Biotech International Ltd. “Sometimes I get goosebumps, sometimes I wake up early in the morning wondering where are we. What are we doing? How do we get there?”

Bharat has already produced about 10 million doses of its Covaxin shot, ahead of an anticipated roll out by the middle of next year.

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in